key: cord-0736850-vgrk7zki authors: Marianetti, Massimo; Pinna, Silvia; Venuti, Angelo; Liguri, Gianfranco title: Olive polyphenols and bioavailable glutathione: Promising results in patients diagnosed with mild Alzheimer's disease date: 2022-03-13 journal: Alzheimers Dement (N Y) DOI: 10.1002/trc2.12278 sha: 59b687d49428c3ca2b643ba414f3a48c405291e9 doc_id: 736850 cord_uid: vgrk7zki INTRODUCTION: Recent studies highlighted the role of olive polyphenols in disrupting the ordered structure of highly cytotoxic amyloid beta protofibrils and the efficacy of a derivatized form of glutathione to counteract neuronal oxidative stress affecting specific brain regions at early stages of Alzheimer's disease (AD) pathogenesis. We performed a randomized cross‐over clinical trial to evaluate their potential benefits in mild AD. METHODS: Oleuropein and S‐acetyl glutathione were administered as dietary supplement for 6 months to 18 patients diagnosed for probable mild AD according to International Working Group 2 criteria. Patients underwent an extensive cognitive and behavioral neuropsychological test battery at the beginning and end of the study to evaluate cognitive deterioration, memory, visuospatial abilities, attention, language, executive functions, and behavioral disorders. We compared patients receiving treatment to patients receiving no treatment. RESULTS: All the measured neurocognitive parameters stabilized or improved after the treatment in all patients. DISCUSSION: Dietary supplement with olive polyphenols and bioavailable glutathione could be useful for patients diagnosed with mild AD. C. elegans, and in CRND8 transgenic mice, a model of Aß plaque deposition. 5 In particular, transgenic mice fed a normal diet supplemented with Ole showed a dose-dependent protection against cognitive deterioration compared to normally fed littermates. At the tissue level, these mice displayed a significant improvement of synaptic function, plaque load, neurogenesis, and neuroinflammation. 6 Glutathione, the main antioxidant defense in the body, is a metabolite with one of the highest concentrations in mammalian tissue cells. Its concentration (between 1 and 10 mM depending on the cell type) decreases with age and in specific central nervous system regions in AD patients. 7 When taken orally, glutathione as such is unable to cross the alimentary canal intact as it undergoes a hydrolytic cleavage catalyzed by digestive enzymes, in particular by pancreatic peptidase and the intestinal wall. 8 In recent years, S-acetyl glutathione (SAG) and glutathione derivatives conjugated with long-chain fatty acid conjugates have been shown to be highly bioavailable from preclinical and clinical studies. These glutathione derivatives have proven to be capable of significantly increasing the intracellular concentration of the tripeptide even when supplied at concentration levels of orders of magnitude lower than those reached within the cells. 9 This effect is believed to be the result of a trapping process by cells, which do not allow the release of glutathione penetrated as thioesters and subsequently hydrolyzed by intracellular thioesterases. In particular, glutathione derivatives with omega-3 fatty acids such as S-linolenoyl glutathione have proven particularly effective in counteracting oxidative stress in the neurons of patients with AD and in preventing cell death in cultures of human neurons exposed to oxidative stress induced by hydrogen peroxide and Aβ 42 . 9 The association with a bioavailable form of glutathione is therefore expected to further ameliorate Ole neuroprotection by counteracting oxidative stress, a dishomeostasis not directly relieved by Ole in TgCRND8 mice. 6 Even if the possible therapeutic role of many antioxidants in AD has been deeply investigated, no literature yet ascribes the potential benefits of these two molecules for patients who have already developed AD. 7 On the basis of the above-reported findings from preclinical studies, we performed a randomized cross-over clinical trial by enrolling patients with mild AD diagnosis to which a nutraceutical formulation containing Ole, SAG, and a low-dose combination of other well-known inhibitors of oxidative stress (vitamins B6, B12, E, and D3; piperine; bacopa) was administered daily, to assess protection against neuropsychological deterioration. The study was carried out in accordance with the Code of Ethics of the Overall, the treatment seems to successfully diminish the effect of neurodegeneration in all neuropsychological outcome variables observed. Even if the number of patients is very small and there is no placebo control, these relevant effects are unexpected and are tentatively ascribed by authors to a synergistic effect of the active compounds of the nutraceutical formulation toward neurotoxic activity of amyloid protofibrils and neuronal oxidative stress, two hallmarks in early stages of AD pathogenesis. Reviewing literature about this topic, we considered the SAG and Ole interaction as primarily responsible for the proposed metabolic synergy. 20 Despite the "proof-of-concept" character of this study, the authors believe that the results are impactful considering the lack of therapeutic perspectives for AD. We are planning to perform a double-blind randomized controlled trial with a larger number of patients including neuropsychological measures and other validated AD biomarkers. At the moment, there is encouraging preliminary evidence that the described treatment could be proficiently adopted for patients with mild cognitive impairment or mild AD. The amyloid hypothesis of Alzheimer's disease at 25 years Alzheimer's disease drugdevelopment pipeline: few candidates, frequent failures Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases Alzheimer's Disease Neuroimaging Initiative. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons Oleuropein, an anti-oxidant polyphenol constituent of olive promotes α-secretase cleavage of the amyloid precursor protein (AαPP) The polyphenol oleuropein aglycone protects TgCRND8 mice against Aβ plaque pathology for the Cache County Study Group (2004) Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements The systemic availability of oral glutathione Protective effect of new Sacylglutathione derivatives against amyloid-induced oxidative stress Mini Mental State: a practical method for grading the cognitive state of patients for the clinician Improved screening for dementia: combining the clock drawing test and the Mini-Mental State Examination Presented at «The 4th International Nice/Springfield Alzheimer Symposium» Nice The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery Standardizzazione e taratura italiana di test neuropsicologici The Frontal Assessment Battery (FAB): normative values in an Italian population sample Aphasie Test (Edizione italiana) Normative values of a new cognitive estimation task: the weight and time estimation test Reliability and validity of the Apathy Evaluation Scale The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials Olive phenolics increase glutathione levels in healthy volunteers Olive polyphenols and bioavailable glutathione: Promising results in patients diagnosed with mild Alzheimer Alzheimer's Dement The authors thank Enrico Calvanese, MPA/ID 2020 and Luca Giani, MPP candidate-Harvard University, Kennedy School, for their skilled advising and support in processing data for statistical analysis; Innbiotec Pharma s.r.l., for developing the nutraceutical formulation;and Igea Pharma NV for supplying the product (commercialized as Alz1Tab/Euvitase). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.